Selectively disrupting lysine acetyltransferase p300 and ZEB1 interaction prevents tumor progression while enhancing antitumor immunity
Proceedings of the National Academy of Sciences, Volume 123, Issue 46, November 2026. SignificanceSelectively disrupting lysine acetyltransferase p300 interaction with specific pro-oncogenic targets serves as a safe and effective strategy for cancer treatment.